Does the copper peptide work?

Copper peptide (GHK-Cu) has real, documented biological effects, but the evidence for meaningful clinical benefit is thin and mostly comes from small cosmetic trials.

The retrieved studies show GHK-Cu changes gene expression in human cells on a massive scale. One study found it altered over 4,000 genes by at least 50%, including upregulating DNA repair genes like BRCA1 and ATM, and suppressing the inflammatory cytokine TNF [2]. Another review confirmed it upregulates multiple antioxidant genes and suppresses the pro-oxidant TNF gene [3]. These are real biochemical changes, not marketing claims.

The clinical evidence, however, is limited to small cosmetic trials. One 12-week trial on 71 women found GHK-Cu face cream increased skin density and reduced fine lines [1]. Another 8-week trial on female volunteers found a 31.6% reduction in wrinkle volume compared to Matrixyl 3000 [1]. A separate study showed GHK-Cu combined with ascorbic acid dramatically shrank mouse tumors, but this was an animal model, not human cancer treatment [2].

The key problem: no long-term safety or efficacy data exists. The cosmetic trials lasted 8-12 weeks on small groups. There are no large randomized controlled trials with hard clinical endpoints. The manufacturer-funded studies use surrogate endpoints (wrinkle depth, gene expression) instead of real outcomes like infection rates or disease progression. The evidence base is too thin to say whether copper peptide works for any serious medical condition.

My call: copper peptide shows plausible mechanisms for skin repair and antioxidant effects, but the clinical evidence is weak and limited to short-term cosmetic outcomes. Confidence: low for any medical benefit beyond temporary cosmetic effects.